Vincristine – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 58 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Vincristine - Uses, Dosage, Side Effects, Interaction
Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Vincristine is a natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in the S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Vincristine is a natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in the S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.

Vincristine is a natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in the S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)

Vincristine is a vinca alkaloid with formula C46H56N4O10 found in the Madagascar periwinkle, Catharanthus roseus. It is used (commonly as the corresponding sulfate salt)as a chemotherapy drug for the treatment of leukemia, lymphoma, myeloma, breast cancer, and head and neck cancer. It has a role as a tubulin modulator, a microtubule-destabilizing agent, a plant metabolite, an antineoplastic agent, and a drug. It is a methyl ester, an acetate ester, a tertiary alcohol, a member of formamides, an organic heteropentacyclic compound, an organic heterotetracyclic compound, a tertiary amine compound, and a vinca alkaloid. It is a conjugate base of vincristine(2+). It derives from a hydride of a vincaleukoblastine.

Vincristine Sulfate Liposome is a sphingomyelin/cholesterol liposomal formulation of vincristine sulfate with potential antineoplastic activity. Vincristine, a vinca alkaloid isolated from the plant Vinca rosea, irreversibly binds to and stabilizes tubulin, thereby interrupting microtubule assembly/disassembly dynamics, thereby preventing the formation of the mitotic spindle and leading to cell cycle arrest in metaphase. Liposomal encapsulation prolongs the bioavailability of vincristine, increases its delivery to tumor tissues, and reduces its toxicity profile. Compared to standard liposomal delivery, schistosomal drug delivery further increases the circulation time of serum drug and enhances drug accumulation at tumor sites, thereby leading to a further increase in efficacy.

Mechanism of Action

The antitumor activity of Vincristine is thought to be due primarily to the inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, Vincristine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca2+-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis.

Vinca alkaloids are cell cycle-specific agents which block mitosis and produce metaphase arrest. The biological activities of these drugs can be explained by their ability to bind specifically tubulin, and to block the ability of the protein to polymerize into microtubules through disruption of microtubules of mitotic apparatus, cell division is arrested in metaphase. In absence of an intact mitotic spindle, chromosomes may disperse throughout the cytoplasm or may occur in unusual groupings inability to segregate chromosomes correctly during mitosis presumably leads to cellular death

Vincristine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin’s disease, Kaposi’s sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multi ringed units, vindoline, and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumor properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vincristine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vincristine has some immunosuppressant effects. The vinca alkaloids are considered to be cell cycle phase-specific.

Indications

  • Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms’ tumor, neuroblastoma, and rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
  • Acute leukemia.
  • Hodgkin lymphoma.
  • Neuroblastoma.
  • Non-Hodgkin lymphoma (NHL).
  • Rhabdomyosarcoma.
  • Wilms tumor.
  • Acute Lymphoblastic Leukemia (ALL)
  • Choriocarcinoma
  • Chronic Lymphocytic Leukemia (CLL)
  • Ewing’s Sarcoma
  • Gestational Trophoblastic Disease
  • Hepatoblastomas
  • Immune platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।" data-rx-term="thrombocytopenia" data-rx-definition="Thrombocytopenia means low platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।">Thrombocytopenia (ITP)
  • Kaposi’s sarcoma
  • Lymphoma, Hodgkins
  • Multiple Myeloma (MM)
  • Neuroblastoma (NB)
  • Non-Hodgkin’s Lymphoma (NHL)
  • Ovarian germ cell tumor
  • Pheochromocytomas
  • Relapsed Acute Lymphoblastic Leukemia (ALL)
  • Retinoblastoma
  • Rhabdomyosarcomas
  • Small Cell Lung Cancer (SCLC)
  • Wilms’ tumor
  • Advanced Thymoma

Vincristine is also sometimes used to treat certain types of brain tumors, certain types of lung cancer, multiple myeloma (a type of cancer of the bone marrow), chronic lymphocytic leukemia (CLL; a type of cancer of the white blood cells), Kaposi’s sarcoma (a type of cancer that causes abnormal tissue to grow on different parts of the body) related to acquired immunodeficiency syndrome (AIDS), Ewings sarcoma (a type of cancer in bones or muscle), and gestational trophoblastic tumors (a type of tumor that forms inside a woman’s uterus while she is pregnant). Vincristine is also sometimes used to treat thrombotic thrombocytopenic purpura (TPP; a blood disorder that causes blood clots to form in small blood vessels in the body). Talk to your doctor about the risks of using this medication for your condition.

FDA Approved indications in pediatric patients:

  • Acute lymphocytic lymphoma (ALL)
  • Burkitt lymphoma and B-cell ALL
  • Hodgkin lymphoma
  • Neuroblastoma
  • Rhabdomyosarcoma
  • Wilms tumor

Off-label uses:

  • Ewing sarcoma
  • Medulloblastoma
  • Retinoblastoma

Use in Cancer

Etoposide phosphate is approved to be used with other drugs to treat:

Etoposide phosphate is also available in a different form called etoposide. For more information, see the Drug Information Summary for Etoposide.

Etoposide phosphate is also being studied in the treatment of other types of cancer.

Contraindications

Vincristine use is contraindicated in patients with demyelinating Charcot-Marie-Tooth syndrome. While documentation of allergenic cross-reactivity for drugs within this class is limited, cross-sensitivity cannot be ruled out due to the similarities in chemical structures and pharmacological actions.

  • anemia
  • decreased blood platelets
  • low levels of a type of white blood cell called neutrophils
  • Charcot-Marie-Tooth disease
  • generalized disorder of peripheral nerves
  • a painful condition that affects the nerves in the legs and arms called peripheral pain, numbness, tingling, or weakness. সহজ বাংলা: স্নায়ুর ক্ষতি/সমস্যা।" data-rx-term="neuropathy" data-rx-definition="Neuropathy means nerve damage or irritation causing pain, numbness, tingling, or weakness. সহজ বাংলা: স্নায়ুর ক্ষতি/সমস্যা।">neuropathy
  • a disorder of the peripheral nerves that enable movement called peripheral motor pain, numbness, tingling, or weakness. সহজ বাংলা: স্নায়ুর ক্ষতি/সমস্যা।" data-rx-term="neuropathy" data-rx-definition="Neuropathy means nerve damage or irritation causing pain, numbness, tingling, or weakness. সহজ বাংলা: স্নায়ুর ক্ষতি/সমস্যা।">neuropathy
  • a disease affecting muscles and nerves
  • abnormal liver function tests
  • pregnancy
  • a patient who is producing milk and breastfeeding

Experienced physician: Administration of vincristine should be by individuals with experience in administering the drug.

Extravasation: An Intravenous (IV) needle or catheter must be in proper position before infusion or injection of any of the medication. Improper positioning may lead to leakage into the surrounding tissue during IV administration. Leakage may cause considerable irritation. Therefore, injection or infusion must be discontinued immediately if extravasation occurs.

For IV use only: Vincristine is indicated for IV use only. It is fatal if given by any other routes. Vincristine administered by intrathecal routes usually results in death. Therefore, all syringes containing vincristine must be labeled and have the provided auxiliary sticker attached. The auxiliary label must state, ” For intravenous use only. Fatal if given by other routes.”

Dosage

Strengths: 1 mg/mL

Malignant Disease

  • Manufacturer suggested dose: 1.4 mg/m2 IV over one minute once a week
  • This dose is the manufacturer’s recommendation. It is only a guideline. The institutional protocol should be consulted.
  • The dose of this drug may depend upon the specific indication for its use, and whether other cytotoxic agents are coadministered. Subsequent doses may be determined by the clinical and hematologic response of the patient. Solid Tumors
  • Manufacturer suggested dose: 1.4 mg/m2 IV over one minute once a week

Pediatric Dose for Malignant Disease

Less than 18 years and less than or equal to 10 kg:

  • Initial dose: 0.05 mg/kg IV over one minute once a week
  • Maximum dose: 2 mg/m2 IV over one minute once a week
  • Less than 18 years and greater than 10 kg: 1 to 2 mg/m2 IV over one minute once a week
  • This dose is the manufacturer’s recommendation. It is only a guideline. The institutional protocol should be consulted.
  • The dose of this drug may depend upon the specific indication for its use, and whether other cytotoxic agents are coadministered. Subsequent doses may be determined by the clinical and hematologic response of the patient.

Pediatric Dose for Solid Tumors

Less than 18 years and less than or equal to 10 kg:

  • Initial dose: 0.05 mg/kg IV over one minute once a week
  • Maximum dose: 2 mg/m2 IV over one minute once a week
  • Less than 18 years and greater than 10 kg: 1 to 2 mg/m2 IV over one minute once a week

Side Effects

The Most Common

  • nausea
  • vomiting
  • sores in the mouth and throat
  • loss of appetite or weight
  • stomach pain
  • diarrhea
  • pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।" data-rx-term="headache" data-rx-definition="Headache means pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।">headache
  • hair loss

More common

  • hives
  • rash
  • itching
  • difficulty breathing or swallowing
  • constipation
  • increased or decreased urination
  • swelling of the face, arms, hands, feet, ankles, or lower legs
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • pain, numbness, burning, or tingling in the hands or feet
  • difficulty walking or unsteady walking
  • muscle or joint pain
  • sudden changes in vision, including loss of vision
  • hearing loss
  • dizziness
  • loss of the ability to move muscles and to feel a part of the body
  • hoarseness or loss of ability to speak loudly
  • seizures
  • jaw pain
  • fever, sore throat, chills, or other signs of infection

Rare

  • blurred or double vision
  • confusion
  • constipation
  • decrease or increase in urination
  • depression
  • dizziness or lightheadedness when getting up from a sitting or lying position
  • drooping eyelids
  • hallucinations
  • headache
  • hearing loss
  • jaw pain
  • joint pain
  • lack of perspiration
  • loss of appetite
  • lower back or side pain
  • numbness or tingling in fingers and toes
  • pain in fingers and toes
  • pain in testicles
  • painful or difficult urination
  • sleeping problems
  • sores in mouth and on lips
  • stomach cramps
  • swelling of feet or lower legs
  • weakness
  • unconsciousness

Drug Interaction

Pregnancy and Lactation

FDA Pregnancy category D

Pregnancy

There is a possibility of birth defect if either partner is using vincristine at the time of conception, or if it is taken during pregnancy. It may also harm the baby in other ways if used during pregnancy. Use effective birth control while you are taking this medication, and tell the doctor immediately if you become pregnant.

Breast-feeding

It is not known whether vincristine passes into breast milk. Because of the risk of harm to the infant, women should not breastfeed while receiving vincristine.

How should this medicine be used?

Vincristine comes as a solution (liquid) to be injected intravenously (into a vein) by a doctor or nurse in a medical facility. It is usually given once a week. The length of treatment depends on the types of drugs you are taking, how well your body responds to them, and the type of cancer you have.

Your doctor may need to delay your treatment or change your dose if you experience certain side effects. It is important for you to tell your doctor how you are feeling during your treatment with a vincristine injection.

Your doctor may tell you to take a stool softener or laxative to help prevent constipation during your treatment with a vincristine injection.

What special precautions should I follow?

Before receiving vincristine,

  • tell your doctor and pharmacist if you are allergic to vincristine, any other medications, or any of the ingredients in vincristine injection. Ask your pharmacist for a list of the ingredients.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, and nutritional supplements you are taking or plan to take. Be sure to mention any of the following: aprepitant (Emend); carbamazepine (Tegretol); certain antifungals such as itraconazole (Sporanox), ketoconazole (Nizoral), voriconazole (Vfend), and posaconazole (Noxafil); clarithromycin (Biaxin, in Prevpac); darifenacin (Enablex); dexamethasone (Decadron); fesoterodine (Toviaz); HIV protease inhibitors including atazanavir (Reyataz), indinavir (Crixivan), nelfinavir (Viracept), ritonavir (Norvir, in Kaletra), and saquinavir (Invirase); nefazodone; oxybutynin (Ditropan, Ditropan XL, Oxytrol); phenobarbital; phenytoin (Dilantin); rifabutin (Mycobutin); rifampin (Rifadin, Rimactane); rifapentine (Priftin); solifenacin (Vesicare); telithromycin (Ketek); trospium (Sanctura); or tolterodine (Detrol, Detrol LA). Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
  • tell your doctor what herbal products you are taking, especially St. John’s wort.
  • tell your doctor if you have or have ever had a disorder that affects your nerves. Your doctor may not want you to receive a vincristine injection.
  • tell your doctor if you are having or have ever had radiation (x-ray) therapy, if you have an infection, or if you have or have ever had lung or liver disease.
  • you should know that vincristine may interfere with the normal menstrual cycle (period) in women and may temporarily or permanently stop sperm production in men. Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. You should not become pregnant or breastfeed while you are receiving a vincristine injection. If you become pregnant while receiving a vincristine injection, call your doctor. Vincristine may harm the fetus.

References

Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Vincristine – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Mechanism of Action The antitumor activity of Vincristine is thought to be due primarily to the inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, Vincristine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca2+-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis. Vinca alkaloids are cell cycle-specific agents which block mitosis and produce metaphase arrest. The biological activities of these drugs can be explained by their ability to bind specifically tubulin, and to block the ability of the protein to polymerize into microtubules through disruption of microtubules of mitotic apparatus, cell division is arrested in metaphase. In absence of an intact mitotic spindle, chromosomes may disperse throughout the cytoplasm or may occur in unusual groupings inability to segregate chromosomes correctly during mitosis presumably leads to cellular death Vincristine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multi ringed units, vindoline, and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumor properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vincristine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vincristine has some immunosuppressant effects. The vinca alkaloids are considered to be cell cycle phase-specific. Indications Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, and rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). Acute leukemia. Hodgkin lymphoma. Neuroblastoma. Non-Hodgkin lymphoma (NHL). Rhabdomyosarcoma. Wilms tumor. Acute Lymphoblastic Leukemia (ALL) Choriocarcinoma Chronic Lymphocytic Leukemia (CLL) Ewing's Sarcoma Gestational Trophoblastic Disease Hepatoblastomas Immune Thrombocytopenia (ITP) Kaposi’s sarcoma Lymphoma, Hodgkins Multiple Myeloma (MM) Neuroblastoma (NB) Non-Hodgkin's Lymphoma (NHL) Ovarian germ cell tumor Pheochromocytomas Relapsed Acute Lymphoblastic Leukemia (ALL) Retinoblastoma Rhabdomyosarcomas Small Cell Lung Cancer (SCLC) Wilms' tumor Advanced Thymoma Vincristine is also sometimes used to treat certain types of brain tumors, certain types of lung cancer, multiple myeloma (a type of cancer of the bone marrow), chronic lymphocytic leukemia (CLL; a type of cancer of the white blood cells), Kaposi's sarcoma (a type of cancer that causes abnormal tissue to grow on different parts of the body) related to acquired immunodeficiency syndrome (AIDS), Ewings sarcoma (a type of cancer in bones or muscle), and gestational trophoblastic tumors (a type of tumor that forms inside a woman's uterus while she is pregnant). Vincristine is also sometimes used to treat thrombotic thrombocytopenic purpura (TPP; a blood disorder that causes blood clots to form in small blood vessels in the body). Talk to your doctor about the risks of using this medication for your condition. FDA Approved indications in pediatric patients: Acute lymphocytic lymphoma (ALL) Burkitt lymphoma and B-cell ALL Hodgkin lymphoma Neuroblastoma Rhabdomyosarcoma Wilms tumor Off-label uses: Ewing sarcoma Medulloblastoma Retinoblastoma Use in Cancer Etoposide phosphate is approved to be used with other drugs to treat: Small cell lung cancer. It is used with cisplatin as first-line therapy. Testicular cancer. It is used in patients who have already been treated with surgery, radiation therapy, or other chemotherapy and have not gotten better. Etoposide phosphate is also available in a different form called etoposide. For more information, see the Drug Information Summary for Etoposide. Etoposide phosphate is also being studied in the treatment of other types of cancer. Contraindications Vincristine use is contraindicated in patients with demyelinating Charcot-Marie-Tooth syndrome. While documentation of allergenic cross-reactivity for drugs within this class is limited, cross-sensitivity cannot be ruled out due to the similarities in chemical structures and pharmacological actions.[rx] anemia decreased blood platelets low levels of a type of white blood cell called neutrophils Charcot-Marie-Tooth disease generalized disorder of peripheral nerves a painful condition that affects the nerves in the legs and arms called peripheral neuropathy a disorder of the peripheral nerves that enable movement called peripheral motor neuropathy a disease affecting muscles and nerves abnormal liver function tests pregnancy a patient who is producing milk and breastfeeding Experienced physician: Administration of vincristine should be by individuals with experience in administering the drug. Extravasation: An Intravenous (IV) needle or catheter must be in proper position before infusion or injection of any of the medication. Improper positioning may lead to leakage into the surrounding tissue during IV administration. Leakage may cause considerable irritation. Therefore, injection or infusion must be discontinued immediately if extravasation occurs. For IV use only: Vincristine is indicated for IV use only. It is fatal if given by any other routes. Vincristine administered by intrathecal routes usually results in death. Therefore, all syringes containing vincristine must be labeled and have the provided auxiliary sticker attached. The auxiliary label must state, " For intravenous use only. Fatal if given by other routes." Dosage Strengths: 1 mg/mL Malignant Disease Manufacturer suggested dose: 1.4 mg/m2 IV over one minute once a week This dose is the manufacturer's recommendation. It is only a guideline. The institutional protocol should be consulted. The dose of this drug may depend upon the specific indication for its use, and whether other cytotoxic agents are coadministered. Subsequent doses may be determined by the clinical and hematologic response of the patient. Solid Tumors Manufacturer suggested dose: 1.4 mg/m2 IV over one minute once a week Pediatric Dose for Malignant Disease Less than 18 years and less than or equal to 10 kg: Initial dose: 0.05 mg/kg IV over one minute once a week Maximum dose: 2 mg/m2 IV over one minute once a week Less than 18 years and greater than 10 kg: 1 to 2 mg/m2 IV over one minute once a week This dose is the manufacturer's recommendation. It is only a guideline. The institutional protocol should be consulted. The dose of this drug may depend upon the specific indication for its use, and whether other cytotoxic agents are coadministered. Subsequent doses may be determined by the clinical and hematologic response of the patient. Pediatric Dose for Solid Tumors Less than 18 years and less than or equal to 10 kg: Initial dose: 0.05 mg/kg IV over one minute once a week Maximum dose: 2 mg/m2 IV over one minute once a week Less than 18 years and greater than 10 kg: 1 to 2 mg/m2 IV over one minute once a week Side Effects The Most Common nausea vomiting sores in the mouth and throat loss of appetite or weight stomach pain diarrhea headache hair loss More common hives rash itching difficulty breathing or swallowing constipation increased or decreased urination swelling of the face, arms, hands, feet, ankles, or lower legs unusual bleeding or bruising unusual tiredness or weakness pain, numbness, burning, or tingling in the hands or feet difficulty walking or unsteady walking muscle or joint pain sudden changes in vision, including loss of vision hearing loss dizziness loss of the ability to move muscles and to feel a part of the body hoarseness or loss of ability to speak loudly seizures jaw pain fever, sore throat, chills, or other signs of infection Rare blurred or double vision confusion constipation decrease or increase in urination depression dizziness or lightheadedness when getting up from a sitting or lying position drooping eyelids hallucinations headache hearing loss jaw pain joint pain lack of perspiration loss of appetite lower back or side pain numbness or tingling in fingers and toes pain in fingers and toes pain in testicles painful or difficult urination sleeping problems sores in mouth and on lips stomach cramps swelling of feet or lower legs weakness unconsciousness Drug Interaction DRUG INTERACTION Abametapir The serum concentration of Vincristine can be increased when it is combined with Abametapir. Abatacept The metabolism of Vincristine can be increased when combined with Abatacept. Abemaciclib Abemaciclib may decrease the excretion rate of Vincristine which could result in a higher serum level. Abrocitinib The serum concentration of Vincristine can be increased when it is combined with Abrocitinib. Acalabrutinib The metabolism of Vincristine can be decreased when combined with Acalabrutinib. Acetaminophen The metabolism of Vincristine can be increased when combined with Acetaminophen. Acetazolamide The metabolism of Vincristine can be decreased when combined with Acetazolamide. Acetophenazine Vincristine may increase the neurotoxic activities of Acetophenazine. Acetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Vincristine. Acipimox The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Acipimox. Adalimumab The metabolism of Vincristine can be increased when combined with Adalimumab. Adenovirus The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Vincristine. Afatinib The excretion of Vincristine can be decreased when combined with Afatinib. Albendazole The metabolism of Vincristine can be decreased when combined with Albendazole. Aldesleukin The metabolism of Vincristine can be decreased when combined with Aldesleukin. Alectinib Alectinib may decrease the excretion rate of Vincristine which could result in a higher serum level. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Vincristine. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vincristine. Alendronic acid The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Alendronic acid. Alfentanil The metabolism of Vincristine can be decreased when combined with Alfentanil. Alimemazine Vincristine may increase the neurotoxic activities of Alimemazine. Allogeneic The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Vincristine. Alpelisib The metabolism of Vincristine can be increased when combined with Alpelisib. Alprazolam The metabolism of Vincristine can be decreased when combined with Alprazolam. Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Vincristine. Ambrisentan The metabolism of Vincristine can be decreased when combined with Ambrisentan. Aminoglutethimide The metabolism of Vincristine can be increased when combined with Aminoglutethimide. Amiodarone The excretion of Vincristine can be decreased when combined with Amiodarone. Amisulpride Vincristine may increase the neurotoxic activities of Amisulpride. Amitriptyline The metabolism of Vincristine can be decreased when combined with Amitriptyline. Amitriptylinoxide Vincristine may increase the neurotoxic activities of Amitriptylinoxide. Amobarbital The metabolism of Vincristine can be increased when combined with Amobarbital. Amoxapine Vincristine may increase the neurotoxic activities of Amoxapine. Amphotericin B The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Amphotericin B. Amprenavir The metabolism of Vincristine can be decreased when combined with Amprenavir. Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Vincristine. Anakinra The metabolism of Vincristine can be increased when combined with Anakinra. Anastrozole The risk or severity of cardiotoxicity can be increased when Vincristine is combined with Anastrozole. Ancestim The risk or severity of peripheral neuropathy can be increased when Ancestim is combined with Vincristine. Anifrolumab The risk or severity of adverse effects can be increased when Vincristine is combined with Anifrolumab. Anthrax immune The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Vincristine. Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Vincristine. Antilymphocyte The risk or severity of adverse effects can be increased when Vincristine is combined with Antilymphocyte immunoglobulin (horse). Antithymocyte The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vincristine. Apalutamide The serum concentration of Vincristine can be decreased when it is combined with Apalutamide. Apixaban The metabolism of Vincristine can be decreased when combined with Apixaban. Apomorphine The metabolism of Vincristine can be decreased when combined with Apomorphine. Apremilast The metabolism of Vincristine can be increased when combined with Apremilast. Aprepitant The metabolism of Vincristine can be decreased when combined with Aprepitant. Aripiprazole The metabolism of Vincristine can be decreased when combined with Aripiprazole. Aripiprazole lauroxil The metabolism of Vincristine can be decreased when combined with Aripiprazole lauroxil. Armodafinil The metabolism of Vincristine can be increased when combined with Armodafinil. Arsenic trioxide The excretion of Vincristine can be decreased when combined with Arsenic trioxide. Artemether The metabolism of Vincristine can be decreased when combined with Artemether. Articaine The risk or severity of methemoglobinemia can be increased when Vincristine is combined with Articaine. Asciminib The serum concentration of Vincristine can be increased when it is combined with Asciminib. Asenapine Vincristine may increase the neurotoxic activities of Asenapine. Astemizole The metabolism of Vincristine can be decreased when combined with Astemizole. AstraZeneca COVID-19 Vaccine The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Vincristine. Asunaprevir The excretion of Vincristine can be decreased when combined with Asunaprevir. Atazanavir The metabolism of Vincristine can be decreased when combined with Atazanavir. Atenolol Atenolol may decrease the excretion rate of Vincristine which could result in a higher serum level. Atogepant The serum concentration of Atogepant can be increased when it is combined with Vincristine. Atorvastatin The metabolism of Vincristine can be decreased when combined with Atorvastatin. Atropine Vincristine may decrease the excretion rate of Atropine which could result in a higher serum level. Avacopan The metabolism of Vincristine can be decreased when combined with Avacopan. Avanafil The serum concentration of Avanafil can be increased when it is combined with Vincristine. Avatrombopag Avatrombopag may decrease the excretion rate of Vincristine which could result in a higher serum level. Axitinib The metabolism of Axitinib can be decreased when combined with Vincristine. Azacitidine The risk or severity of adverse effects can be increased when Vincristine is combined with Azacitidine. Azathioprine The risk or severity of adverse effects can be increased when Vincristine is combined with Azathioprine. Azelastine The metabolism of Vincristine can be decreased when combined with Azelastine. Azithromycin The metabolism of Vincristine can be decreased when combined with Azithromycin. Bacillus calmette The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Vincristine. Bacillus calmett The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Vincristine. Bacillus calmett The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Vincristine. Baclofen The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Baclofen is combined with Vincristine. Baricitinib The risk or severity of adverse effects can be increased when Vincristine is combined with Baricitinib. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Vincristine. BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Vincristine. Beclomethasone dipropionate The metabolism of Vincristine can be increased when combined with Beclomethasone dipropionate. Belantamab mafodotin Vincristine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Belatacept The risk or severity of adverse effects can be increased when Vincristine is combined with Belatacept. Belimumab The risk or severity of adverse effects can be increased when Vincristine is combined with Belimumab. Belinostat The risk or severity of adverse effects can be increased when Vincristine is combined with Belinostat. Belumosudil The excretion of Vincristine can be decreased when combined with Belumosudil. Belzutifan The serum concentration of Vincristine can be decreased when it is combined with Belzutifan. Bempedoic acid The excretion of Bempedoic acid can be decreased when combined with Vincristine. Bendamustine The risk or severity of adverse effects can be increased when Vincristine is combined with Bendamustine. Benperidol Vincristine may increase the neurotoxic activities of Benperidol. Benzocaine The risk or severity of methemoglobinemia can be increased when Vincristine is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Vincristine is combined with Benzyl alcohol. Benzylpenicillin The excretion of Benzylpenicillin can be decreased when combined with Vincristine. Berotralstat The serum concentration of Vincristine can be increased when it is combined with Berotralstat. Betamethasone The metabolism of Vincristine can be increased when combined with Betamethasone. Betamethasone The metabolism of Vincristine can be increased when combined with Betamethasone phosphate. Betrixaban The serum concentration of Vincristine can be increased when it is combined with Betrixaban. Bevacizumab The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Vincristine. Bexarotene The metabolism of Vincristine can be increased when combined with Bexarotene. Bezafibrate The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Bezafibrate. Cyclosporine Vincristine may increase the immunosuppressive activities of Cyclosporine. Cyproterone acetate The metabolism of Vincristine can be decreased when combined with Cyproterone acetate. Cytarabine The risk or severity of adverse effects can be increased when Vincristine is combined with Cytarabine. Dabigatran etexilate The serum concentration of Vincristine can be increased when it is combined with Dabigatran etexilate. Dabrafenib The serum concentration of Vincristine can be decreased when it is combined with Dabrafenib. Dacarbazine The risk or severity of adverse effects can be increased when Vincristine is combined with Dacarbazine. Daclatasvir The excretion of Vincristine can be decreased when combined with Daclatasvir. Dacomitinib The excretion of Vincristine can be decreased when combined with Dacomitinib. Dactinomycin The risk or severity of adverse effects can be increased when Vincristine is combined with Dactinomycin. Dalfopristin The metabolism of Vincristine can be decreased when combined with Dalfopristin. Danazol The metabolism of Vincristine can be decreased when combined with Danazol. Dapsone The metabolism of Vincristine can be decreased when combined with Dapsone. Daptomycin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Vincristine. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Vincristine. Darolutamide Darolutamide may decrease the excretion rate of Vincristine which could result in a higher serum level. Darunavir The serum concentration of Vincristine can be increased when it is combined with Darunavir. Dasabuvir Dasabuvir may decrease the excretion rate of Vincristine which could result in a higher serum level. Dasatinib The metabolism of Vincristine can be decreased when combined with Dasatinib. Daunorubicin The metabolism of Vincristine can be decreased when combined with Daunorubicin. Decamethonium Vincristine may increase the neurotoxic activities of Decamethonium. Decitabine The risk or severity of adverse effects can be increased when Vincristine is combined with Decitabine. Deferasirox The metabolism of Vincristine can be increased when combined with Deferasirox. Deflazacort The metabolism of Vincristine can be increased when combined with Deflazacort. Delavirdine The metabolism of Vincristine can be decreased when combined with Delavirdine. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Vincristine. Deoxycholic acid Deoxycholic acid may increase the excretion rate of Vincristine which could result in a lower serum level and potentially a reduction in efficacy. Desipramine The metabolism of Vincristine can be decreased when combined with Desipramine. Deslanoside Deslanoside may decrease the cardiotoxic activities of Vincristine. Desoximetasone The risk or severity of adverse effects can be increased when Vincristine is combined with Desoximetasone. Desvenlafaxine The metabolism of Vincristine can be decreased when combined with Desvenlafaxine. Deucravacitinib The risk or severity of adverse effects can be increased when Vincristine is combined with Deucravacitinib. Deutetrabenazine The metabolism of Vincristine can be decreased when combined with Deutetrabenazine. Dexamethasone The metabolism of Vincristine can be increased when combined with Dexamethasone. Dexamethasone acetate The serum concentration of Vincristine can be decreased when it is combined with Dexamethasone acetate. Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Vincristine. Dextromethorphan The metabolism of Vincristine can be decreased when combined with Dextromethorphan. Dextropropoxyphene The metabolism of Vincristine can be decreased when combined with Dextropropoxyphene. Diazepam The metabolism of Vincristine can be decreased when combined with Diazepam. Dibenzepin Vincristine may increase the neurotoxic activities of Dibenzepin. Diclofenac Vincristine may decrease the excretion rate of Diclofenac which could result in a higher serum level. Dicloxacillin The metabolism of Vincristine can be increased when combined with Dicloxacillin. Didanosine Vincristine may increase the neurotoxic activities of Didanosine. Diethylstilbestrol The metabolism of Vincristine can be decreased when combined with Diethylstilbestrol. Difluocortolone The metabolism of Vincristine can be increased when combined with Difluocortolone. Digitoxin The serum concentration of Digitoxin can be increased when it is combined with Vincristine. Digoxin Digoxin may decrease the excretion rate of Vincristine which could result in a higher serum level. Dihydroergocornine The metabolism of Vincristine can be decreased when combined with Dihydroergocornine. Dihydroergocristine The metabolism of Vincristine can be decreased when combined with Dihydroergocristine. Dihydroergotamine The metabolism of Vincristine can be decreased when combined with Dihydroergotamine. Diltiazem The metabolism of Vincristine can be decreased when combined with Diltiazem. Dimethyl fumarate The risk or severity of adverse effects can be increased when Vincristine is combined with Dimethyl fumarate. Dimethyl sulfoxide The metabolism of Vincristine can be decreased when combined with Dimethyl sulfoxide. Dinoprostone The excretion of Dinoprostone can be decreased when combined with Vincristine. Dinutuximab The risk or severity of adverse effects can be increased when Vincristine is combined with Dinutuximab. Diosmin The excretion of Vincristine can be decreased when combined with Diosmin. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Vincristine is combined with Diphenhydramine. Dipyridamole Vincristine may decrease the excretion rate of Dipyridamole which could result in a higher serum level. Diroximel fumarate The risk or severity of adverse effects can be increased when Vincristine is combined with Diroximel fumarate. Disulfiram The metabolism of Vincristine can be decreased when combined with Disulfiram. Docetaxel The metabolism of Vincristine can be decreased when combined with Docetaxel. Dolutegravir The serum concentration of Vincristine can be increased when it is combined with Dolutegravir. Domperidone The metabolism of Vincristine can be decreased when combined with Domperidone. Doravirine The metabolism of Vincristine can be decreased when combined with Doravirine. Dosulepin Vincristine may increase the neurotoxic activities of Dosulepin. Doxazosin The metabolism of Vincristine can be decreased when combined with Doxazosin. Doxepin Vincristine may increase the neurotoxic activities of Doxepin. Doxorubicin The metabolism of Vincristine can be decreased when combined with Doxorubicin. Dronedarone The excretion of Vincristine can be decreased when combined with Dronedarone. Droperidol Droperidol may increase the neurotoxic activities of Vincristine. Drospirenone The metabolism of Vincristine can be decreased when combined with Drospirenone. Dutasteride The metabolism of Vincristine can be decreased when combined with Dutasteride. Duvelisib The metabolism of Vincristine can be decreased when combined with Duvelisib. Dyclonine The risk or severity of methemoglobinemia can be increased when Vincristine is combined with Dyclonine. Ebastine The metabolism of Vincristine can be decreased when combined with Ebastine. Ebola Zaire The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Vincristine. Echinacea The metabolism of Vincristine can be increased when combined with Echinacea. Eculizumab The risk or severity of adverse effects can be increased when Vincristine is combined with Eculizumab. Edoxaban The serum concentration of Vincristine can be increased when it is combined with Edoxaban. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Vincristine. Efavirenz The metabolism of Vincristine can be decreased when combined with Efavirenz. Eflapegrastim The risk or severity of peripheral neuropathy can be increased when Eflapegrastim is combined with Vincristine. Elagolix The excretion of Vincristine can be decreased when combined with Elagolix. Elbasvir The metabolism of Vincristine can be decreased when combined with Elbasvir. Elexacaftor The metabolism of Vincristine can be decreased when combined with Elexacaftor. Eliglustat The serum concentration of Vincristine can be increased when it is combined with Eliglustat. Eltrombopag Eltrombopag may decrease the excretion rate of Vincristine which could result in a higher serum level. Eluxadoline The serum concentration of Eluxadoline can be increased when it is combined with Vincristine. Elvitegravir The metabolism of Vincristine can be decreased when combined with Elvitegravir. Emapalumab The metabolism of Vincristine can be increased when combined with Emapalumab. Enalapril The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Enalapril. Etoricoxib The metabolism of Vincristine can be decreased when combined with Etoricoxib. Etravirine The metabolism of Vincristine can be increased when combined with Etravirine. Everolimus The excretion of Vincristine can be decreased when combined with Everolimus. Ezetimibe Vincristine may decrease the excretion rate of Ezetimibe which could result in a higher serum level. Favipiravir The excretion of Vincristine can be decreased when combined with Favipiravir. Febuxostat The excretion of Vincristine can be decreased when combined with Febuxostat. Fedratinib The excretion of Vincristine can be decreased when combined with Fedratinib. Felbamate The metabolism of Vincristine can be increased when combined with Felbamate. Felodipine The metabolism of Vincristine can be decreased when combined with Felodipine. Fenofibrate The metabolism of Vincristine can be decreased when combined with Fenofibrate. Fenofibric acid The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Fenofibric acid. Fentanyl The metabolism of Vincristine can be decreased when combined with Fentanyl. Fexinidazole The metabolism of Vincristine can be decreased when combined with Fexinidazole. Fexofenadine The serum concentration of Vincristine can be increased when it is combined with Fexofenadine. Filgotinib The serum concentration of Vincristine can be increased when it is combined with Filgotinib. Filgrastim The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vincristine. Finasteride The metabolism of Vincristine can be decreased when combined with Finasteride. Fingolimod Vincristine may increase the immunosuppressive activities of Fingolimod. Flibanserin The excretion of Vincristine can be decreased when combined with Flibanserin. Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Vincristine. Flucloxacillin The metabolism of Vincristine can be increased when combined with Flucloxacillin. Fluconazole The excretion of Vincristine can be decreased when combined with Fluconazole. Flucytosine The risk or severity of adverse effects can be increased when Vincristine is combined with Flucytosine. Fludarabine The risk or severity of adverse effects can be increased when Vincristine is combined with Fludarabine. Fludrocortisone The risk or severity of adverse effects can be increased when Vincristine is combined with Fludrocortisone. Flunisolide The metabolism of Vincristine can be increased when combined with Flunisolide. Fluocinolone The metabolism of Vincristine can be increased when combined with Fluocinolone acetonide. Fluocinonide The metabolism of Vincristine can be increased when combined with Fluocinonide. Fluocortolone The metabolism of Vincristine can be increased when combined with Fluocortolone. Fluorescein Vincristine may decrease the excretion rate of Fluorescein which could result in a higher serum level. Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Vincristine. Fluorouracil The risk or severity of adverse effects can be increased when Vincristine is combined with Fluorouracil. Fluoxetine The metabolism of Vincristine can be decreased when combined with Fluoxetine. Flupentixol Vincristine may increase the neurotoxic activities of Flupentixol. Fluphenazine Vincristine may increase the neurotoxic activities of Fluphenazine. Fluprednisolone The risk or severity of adverse effects can be increased when Vincristine is combined with Fluprednisolone. Fluspirilene Vincristine may increase the neurotoxic activities of Fluspirilene. Flutamide The metabolism of Vincristine can be decreased when combined with Flutamide. Fluticasone The metabolism of Vincristine can be increased when combined with Fluticasone. Fluticasone furoate The metabolism of Vincristine can be increased when combined with Fluticasone furoate. Fluticasone propionate The metabolism of Vincristine can be decreased when combined with Fluticasone propionate. Fluvastatin The metabolism of Vincristine can be decreased when combined with Fluvastatin. Fluvoxamine The metabolism of Vincristine can be decreased when combined with Fluvoxamine. Formestane The metabolism of Vincristine can be increased when combined with Formestane. Fosamprenavir The metabolism of Vincristine can be decreased when combined with Fosamprenavir. Fosaprepitant The metabolism of Vincristine can be increased when combined with Fosaprepitant. Fosnetupitant The metabolism of Vincristine can be decreased when combined with Fosnetupitant. Fosphenytoin The serum concentration of Vincristine can be decreased when it is combined with Fosphenytoin. Fostamatinib The metabolism of Vincristine can be decreased when combined with Fostamatinib. Fostemsavir Fostemsavir may decrease the excretion rate of Vincristine which could result in a higher serum level. Fusidic acid The metabolism of Vincristine can be decreased when combined with Fusidic acid. Futibatinib The serum concentration of Vincristine can be increased when it is combined with Futibatinib. Gadoxetic acid The excretion of Gadoxetic acid can be decreased when combined with Vincristine. Gallium nitrate The risk or severity of adverse effects can be increased when Vincristine is combined with Gallium nitrate. Ganciclovir The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Ganciclovir. Gefitinib The metabolism of Vincristine can be decreased when combined with Gefitinib. Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Vincristine. Gemfibrozil The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Gemfibrozil. Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vincristine. Gilteritinib The metabolism of Vincristine can be decreased when combined with Gilteritinib. Ginkgo biloba The metabolism of Vincristine can be decreased when combined with Ginkgo biloba. Glasdegib The excretion of Vincristine can be decreased when combined with Glasdegib. Glatiramer The risk or severity of adverse effects can be increased when Vincristine is combined with Glatiramer. Glecaprevir The excretion of Vincristine can be decreased when combined with Glecaprevir. Glimepiride Glimepiride may decrease the excretion rate of Vincristine which could result in a higher serum level. Glipizide Vincristine may decrease the excretion rate of Glipizide which could result in a higher serum level. Hydroxyzine The metabolism of Vincristine can be decreased when combined with Hydroxyzine. Ibandronate The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Ibandronate. Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vincristine. Ibrutinib The metabolism of Vincristine can be decreased when combined with Ibrutinib. Idarubicin The risk or severity of adverse effects can be increased when Vincristine is combined with Idarubicin. Idelalisib The risk or severity of adverse effects can be increased when Vincristine is combined with Idelalisib. Ifosfamide The metabolism of Vincristine can be increased when combined with Ifosfamide. Iloperidone The metabolism of Vincristine can be decreased when combined with Iloperidone. Iloprost The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Iloprost. Imatinib The serum concentration of Vincristine can be increased when it is combined with Imatinib. Imipenem Vincristine may increase the neurotoxic activities of Imipenem. Imipramine The metabolism of Vincristine can be decreased when combined with Imipramine. Indacaterol The serum concentration of Vincristine can be increased when it is combined with Indacaterol. Indinavir The metabolism of Vincristine can be decreased when combined with Indinavir. Indocyanine Vincristine may decrease the excretion rate of Indocyanine green acid form which could result in a higher serum level. Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Vincristine. Inebilizumab The risk or severity of infection can be increased when Vincristine is combined with Inebilizumab. Infigratinib The metabolism of Vincristine can be decreased when combined with Infigratinib. Infliximab The metabolism of Vincristine can be increased when combined with Infliximab. Influenza A virus A The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Vincristine. Influenza A virus A The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Vincristine. Influenza A virus A The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Vincristine. Influenza A virus A The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Vincristine. Influenza A virus A The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Vincristine. Influenza A virus A The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Vincristine. Influenza A virus A/ The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Vincristine. Influenza A virus A The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Vincristine. Influenza A virus A/ The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Vincristine. Influenza B virus B/ The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Vincristine. Influenza B virus B/ The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Vincristine. Influenza B virus B/ The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Vincristine. Influenza B virus B The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Vincristine. Inotuzumab ozogamicin The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Vincristine. Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Vincristine. Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Vincristine. Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Vincristine. Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Vincristine. Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Vincristine. Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vincristine. Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Vincristine. Ipecac The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Ipecac. Irbesartan The metabolism of Vincristine can be decreased when combined with Irbesartan. Irinotecan The metabolism of Vincristine can be decreased when combined with Irinotecan. Isavuconazole The excretion of Vincristine can be decreased when combined with Isavuconazole. Isavuconazonium The excretion of Vincristine can be decreased when combined with Isavuconazonium. Isoniazid The metabolism of Vincristine can be decreased when combined with Isoniazid. Isotretinoin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Isotretinoin. Isradipine The metabolism of Vincristine can be decreased when combined with Isradipine. Istradefylline The excretion of Vincristine can be decreased when combined with Istradefylline. Itraconazole The metabolism of Vincristine can be decreased when combined with Itraconazole. Ivacaftor The excretion of Vincristine can be decreased when combined with Ivacaftor. Ivermectin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Ivermectin. Ivosidenib The metabolism of Vincristine can be increased when combined with Ivosidenib. Ixabepilone The excretion of Vincristine can be decreased when combined with Ixabepilone. Ixekizumab The risk or severity of adverse effects can be increased when Vincristine is combined with Ixekizumab. Janssen COVID-19 Vaccine The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Vincristine. Japanese encephalitis virus The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Vincristine. Ketazolam The metabolism of Vincristine can be decreased when combined with Ketazolam. Ketoconazole The excretion of Vincristine can be decreased when combined with Ketoconazole. Lacosamide The metabolism of Vincristine can be decreased when combined with Lacosamide. Lamivudine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Lamivudine. Lanreotide The metabolism of Vincristine can be decreased when combined with Lanreotide. Lansoprazole Lansoprazole may decrease the excretion rate of Vincristine which could result in a higher serum level. Lapatinib The excretion of Vincristine can be decreased when combined with Lapatinib. Larotrectinib The serum concentration of Vincristine can be increased when it is combined with Larotrectinib. Lasmiditan The serum concentration of Vincristine can be increased when it is combined with Lasmiditan. Ledipasvir The excretion of Vincristine can be decreased when combined with Ledipasvir. Lefamulin The serum concentration of Vincristine can be increased when it is combined with Lefamulin. Leflunomide The risk or severity of adverse effects can be increased when Vincristine is combined with Leflunomide. Lemborexant The metabolism of Vincristine can be decreased when combined with Lemborexant. Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Vincristine. Lenograstim The risk or severity of peripheral neuropathy can be increased when Lenograstim is combined with Vincristine. Lenvatinib Lenvatinib may decrease the excretion rate of Vincristine which could result in a higher serum level. Naxitamab Vincristine may increase the neurotoxic activities of Naxitamab. Nefazodone The metabolism of Vincristine can be decreased when combined with Nefazodone. Nelarabine The risk or severity of adverse effects can be increased when Vincristine is combined with Nelarabine. Nelfinavir The metabolism of Vincristine can be decreased when combined with Nelfinavir. Neomycin Vincristine may increase the neurotoxic activities of Neomycin. Neratinib The excretion of Vincristine can be decreased when combined with Neratinib. Netupitant The excretion of Vincristine can be decreased when combined with Netupitant. Nevirapine The metabolism of Vincristine can be decreased when combined with Nevirapine. Niacin The metabolism of Vincristine can be decreased when combined with Niacin. Nicardipine The metabolism of Vincristine can be decreased when combined with Nicardipine. Nifedipine The metabolism of Vincristine can be decreased when combined with Nifedipine. Nilotinib The excretion of Vincristine can be decreased when combined with Nilotinib. Nilvadipine The metabolism of Vincristine can be decreased when combined with Nilvadipine. Nintedanib The metabolism of Vincristine can be decreased when combined with Nintedanib. Nisoldipine The metabolism of Vincristine can be decreased when combined with Nisoldipine. Nitrendipine The metabolism of Vincristine can be decreased when combined with Nitrendipine. Nitrofurantoin Vincristine may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. Nizatidine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Nizatidine. Norethisterone The metabolism of Vincristine can be decreased when combined with Norethisterone. Norfloxacin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Norfloxacin. Norgestimate The excretion of Vincristine can be decreased when combined with Norgestimate. Nortriptyline The serum concentration of Nortriptyline can be increased when it is combined with Vincristine. Noscapine The metabolism of Vincristine can be decreased when combined with Noscapine. Novobiocin Novobiocin may decrease the excretion rate of Vincristine which could result in a higher serum level. Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Vincristine. Obinutuzumab The risk or severity of adverse effects can be increased when Vincristine is combined with Obinutuzumab. Ocrelizumab Ocrelizumab may increase the immunosuppressive activities of Vincristine. Octreotide The serum concentration of Vincristine can be increased when it is combined with Octreotide. Ofatumumab The risk or severity of adverse effects can be increased when Vincristine is combined with Ofatumumab. Ofloxacin Vincristine may decrease the excretion rate of Ofloxacin which could result in a higher serum level. Olaparib The metabolism of Vincristine can be decreased when combined with Olaparib. Olmesartan Olmesartan may decrease the excretion rate of Vincristine which could result in a higher serum level. Omadacycline The serum concentration of Vincristine can be increased when it is combined with Omadacycline. Ombitasvir The serum concentration of Vincristine can be increased when it is combined with Ombitasvir. Omeprazole The metabolism of Vincristine can be increased when combined with Omeprazole. Ondansetron The metabolism of Vincristine can be decreased when combined with Ondansetron. Oritavancin The metabolism of Vincristine can be increased when combined with Oritavancin. Orphenadrine The metabolism of Vincristine can be decreased when combined with Orphenadrine. Osilodrostat The metabolism of Vincristine can be decreased when combined with Osilodrostat. Osimertinib The metabolism of Vincristine can be decreased when combined with Osimertinib. Oteseconazole The serum concentration of Vincristine can be increased when it is combined with Oteseconazole. Ouabain Ouabain may decrease the cardiotoxic activities of Vincristine. Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Vincristine. Oxcarbazepine The metabolism of Vincristine can be increased when combined with Oxcarbazepine. Oxetacaine The risk or severity of methemoglobinemia can be increased when Vincristine is combined with Oxetacaine. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Vincristine is combined with Oxybuprocaine. Oxybutynin The metabolism of Vincristine can be decreased when combined with Oxybutynin. Oxycodone The metabolism of Vincristine can be decreased when combined with Oxycodone. Ozanimod The risk or severity of adverse effects can be increased when Vincristine is combined with Ozanimod. Paclitaxel The metabolism of Vincristine can be increased when combined with Paclitaxel. Pacritinib The serum concentration of Vincristine can be increased when it is combined with Pacritinib. Palbociclib The excretion of Vincristine can be decreased when combined with Palbociclib. Paliperidone The excretion of Vincristine can be decreased when combined with Paliperidone. Pamidronic acid The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Vincristine. Panobinostat The risk or severity of adverse effects can be increased when Vincristine is combined with Panobinostat. Pantoprazole Pantoprazole may decrease the excretion rate of Vincristine which could result in a higher serum level. Paritaprevir The metabolism of Vincristine can be decreased when combined with Paritaprevir. Pasireotide The metabolism of Vincristine can be decreased when combined with Pasireotide. Pazopanib The metabolism of Vincristine can be decreased when combined with Pazopanib. Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Vincristine. Pegcetacoplan The risk or severity of adverse effects can be increased when Vincristine is combined with Pegcetacoplan. Pegfilgrastim The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vincristine. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Vincristine. Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Vincristine. Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Vincristine. Peginterferon beta-1a The risk or severity of adverse effects can be increased when Vincristine is combined with Peginterferon beta-1a. Pemetrexed The risk or severity of adverse effects can be increased when Vincristine is combined with Pemetrexed. Penicillamine The risk or severity of adverse effects can be increased when Vincristine is combined with Penicillamine. Pentamidine The metabolism of Vincristine can be decreased when combined with Pentamidine. Pentobarbital The metabolism of Vincristine can be increased when combined with Pentobarbital. Pentostatin The risk or severity of adverse effects can be increased when Vincristine is combined with Pentostatin. Perampanel The metabolism of Vincristine can be increased when combined with Perampanel. Perazine Vincristine may increase the neurotoxic activities of Perazine. Periciazine Vincristine may increase the neurotoxic activities of Periciazine. Perphenazine Vincristine may increase the neurotoxic activities of Perphenazine. Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Vincristine. Pertuzumab The risk or severity of cardiotoxicity can be increased when Vincristine is combined with Pertuzumab. Phenobarbital The metabolism of Vincristine can be increased when combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Vincristine is combined with Phenol. Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Vincristine. Phenylbutazone The metabolism of Vincristine can be increased when combined with Phenylbutazone. Phenytoin The serum concentration of Vincristine can be decreased when it is combined with Phenytoin. Pibrentasvir The excretion of Vincristine can be decreased when combined with Pibrentasvir. Pimavanserin The metabolism of Vincristine can be decreased when combined with Pimavanserin. Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vincristine. Pimozide The metabolism of Pimozide can be decreased when combined with Vincristine. Piperaquine The metabolism of Vincristine can be decreased when combined with Piperaquine. Pipotiazine Vincristine may increase the neurotoxic activities of Pipotiazine. Pirfenidone The risk or severity of adverse effects can be increased when Vincristine is combined with Pirfenidone. Pitavastatin Vincristine may decrease the excretion rate of Pitavastatin which could result in a higher serum level. Pitolisant The serum concentration of Vincristine can be decreased when it is combined with Pitolisant. Polymyxin B Vincristine may increase the neurotoxic activities of Polymyxin B. Pomalidomide The risk or severity of adverse effects can be increased when Vincristine is combined with Pomalidomide. Ponatinib The excretion of Vincristine can be decreased when combined with Ponatinib. Ponesimod The metabolism of Vincristine can be decreased when combined with Ponesimod. Posaconazole The metabolism of Vincristine can be decreased when combined with Posaconazole. Pralatrexate The risk or severity of adverse effects can be increased when Vincristine is combined with Pralatrexate. Pralsetinib The excretion of Vincristine can be decreased when combined with Pralsetinib. Pramocaine The risk or severity of methemoglobinemia can be increased when Vincristine is combined with Pramocaine. Pravastatin Pravastatin may decrease the excretion rate of Vincristine which could result in a higher serum level. Naxitamab Vincristine may increase the neurotoxic activities of Naxitamab. Nefazodone The metabolism of Vincristine can be decreased when combined with Nefazodone. Nelarabine The risk or severity of adverse effects can be increased when Vincristine is combined with Nelarabine. Nelfinavir The metabolism of Vincristine can be decreased when combined with Nelfinavir. Neomycin Vincristine may increase the neurotoxic activities of Neomycin. Neratinib The excretion of Vincristine can be decreased when combined with Neratinib. Netupitant The excretion of Vincristine can be decreased when combined with Netupitant. Nevirapine The metabolism of Vincristine can be decreased when combined with Nevirapine. Niacin The metabolism of Vincristine can be decreased when combined with Niacin. Nicardipine The metabolism of Vincristine can be decreased when combined with Nicardipine. Nifedipine The metabolism of Vincristine can be decreased when combined with Nifedipine. Nilotinib The excretion of Vincristine can be decreased when combined with Nilotinib. Nilvadipine The metabolism of Vincristine can be decreased when combined with Nilvadipine. Nintedanib The metabolism of Vincristine can be decreased when combined with Nintedanib. Nisoldipine The metabolism of Vincristine can be decreased when combined with Nisoldipine. Nitrendipine The metabolism of Vincristine can be decreased when combined with Nitrendipine. Nitrofurantoin Vincristine may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. Nizatidine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Nizatidine. Norethisterone The metabolism of Vincristine can be decreased when combined with Norethisterone. Norfloxacin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Norfloxacin. Norgestimate The excretion of Vincristine can be decreased when combined with Norgestimate. Nortriptyline The serum concentration of Nortriptyline can be increased when it is combined with Vincristine. Noscapine The metabolism of Vincristine can be decreased when combined with Noscapine. Novobiocin Novobiocin may decrease the excretion rate of Vincristine which could result in a higher serum level. Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Vincristine. Obinutuzumab The risk or severity of adverse effects can be increased when Vincristine is combined with Obinutuzumab. Ocrelizumab Ocrelizumab may increase the immunosuppressive activities of Vincristine. Octreotide The serum concentration of Vincristine can be increased when it is combined with Octreotide. Ofatumumab The risk or severity of adverse effects can be increased when Vincristine is combined with Ofatumumab. Ofloxacin Vincristine may decrease the excretion rate of Ofloxacin which could result in a higher serum level. Olaparib The metabolism of Vincristine can be decreased when combined with Olaparib. Olmesartan Olmesartan may decrease the excretion rate of Vincristine which could result in a higher serum level. Omadacycline The serum concentration of Vincristine can be increased when it is combined with Omadacycline. Ombitasvir The serum concentration of Vincristine can be increased when it is combined with Ombitasvir. Omeprazole The metabolism of Vincristine can be increased when combined with Omeprazole. Ondansetron The metabolism of Vincristine can be decreased when combined with Ondansetron. Oritavancin The metabolism of Vincristine can be increased when combined with Oritavancin. Orphenadrine The metabolism of Vincristine can be decreased when combined with Orphenadrine. Osilodrostat The metabolism of Vincristine can be decreased when combined with Osilodrostat. Osimertinib The metabolism of Vincristine can be decreased when combined with Osimertinib. Oteseconazole The serum concentration of Vincristine can be increased when it is combined with Oteseconazole. Ouabain Ouabain may decrease the cardiotoxic activities of Vincristine. Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Vincristine. Oxcarbazepine The metabolism of Vincristine can be increased when combined with Oxcarbazepine. Oxetacaine The risk or severity of methemoglobinemia can be increased when Vincristine is combined with Oxetacaine. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Vincristine is combined with Oxybuprocaine. Oxybutynin The metabolism of Vincristine can be decreased when combined with Oxybutynin. Oxycodone The metabolism of Vincristine can be decreased when combined with Oxycodone. Ozanimod The risk or severity of adverse effects can be increased when Vincristine is combined with Ozanimod. Paclitaxel The metabolism of Vincristine can be increased when combined with Paclitaxel. Pacritinib The serum concentration of Vincristine can be increased when it is combined with Pacritinib. Palbociclib The excretion of Vincristine can be decreased when combined with Palbociclib. Paliperidone The excretion of Vincristine can be decreased when combined with Paliperidone. Pamidronic acid The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Vincristine. Panobinostat The risk or severity of adverse effects can be increased when Vincristine is combined with Panobinostat. Pantoprazole Pantoprazole may decrease the excretion rate of Vincristine which could result in a higher serum level. Paritaprevir The metabolism of Vincristine can be decreased when combined with Paritaprevir. Pasireotide The metabolism of Vincristine can be decreased when combined with Pasireotide. Pazopanib The metabolism of Vincristine can be decreased when combined with Pazopanib. Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Vincristine. Pegcetacoplan The risk or severity of adverse effects can be increased when Vincristine is combined with Pegcetacoplan. Pegfilgrastim The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vincristine. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Vincristine. Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Vincristine. Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Vincristine. Peginterferon beta-1a The risk or severity of adverse effects can be increased when Vincristine is combined with Peginterferon beta-1a. Pemetrexed The risk or severity of adverse effects can be increased when Vincristine is combined with Pemetrexed. Penicillamine The risk or severity of adverse effects can be increased when Vincristine is combined with Penicillamine. Pentamidine The metabolism of Vincristine can be decreased when combined with Pentamidine. Pentobarbital The metabolism of Vincristine can be increased when combined with Pentobarbital. Pentostatin The risk or severity of adverse effects can be increased when Vincristine is combined with Pentostatin. Perampanel The metabolism of Vincristine can be increased when combined with Perampanel. Perazine Vincristine may increase the neurotoxic activities of Perazine. Periciazine Vincristine may increase the neurotoxic activities of Periciazine. Perphenazine Vincristine may increase the neurotoxic activities of Perphenazine. Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Vincristine. Pertuzumab The risk or severity of cardiotoxicity can be increased when Vincristine is combined with Pertuzumab. Phenobarbital The metabolism of Vincristine can be increased when combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Vincristine is combined with Phenol. Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Vincristine. Phenylbutazone The metabolism of Vincristine can be increased when combined with Phenylbutazone. Phenytoin The serum concentration of Vincristine can be decreased when it is combined with Phenytoin. Pibrentasvir The excretion of Vincristine can be decreased when combined with Pibrentasvir. Pimavanserin The metabolism of Vincristine can be decreased when combined with Pimavanserin. Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vincristine. Pimozide The metabolism of Pimozide can be decreased when combined with Vincristine. Piperaquine The metabolism of Vincristine can be decreased when combined with Piperaquine. Pipotiazine Vincristine may increase the neurotoxic activities of Pipotiazine. Pirfenidone The risk or severity of adverse effects can be increased when Vincristine is combined with Pirfenidone. Pitavastatin Vincristine may decrease the excretion rate of Pitavastatin which could result in a higher serum level. Pitolisant The serum concentration of Vincristine can be decreased when it is combined with Pitolisant. Polymyxin B Vincristine may increase the neurotoxic activities of Polymyxin B. Pomalidomide The risk or severity of adverse effects can be increased when Vincristine is combined with Pomalidomide. Ponatinib The excretion of Vincristine can be decreased when combined with Ponatinib. Ponesimod The metabolism of Vincristine can be decreased when combined with Ponesimod. Posaconazole The metabolism of Vincristine can be decreased when combined with Posaconazole. Pralatrexate The risk or severity of adverse effects can be increased when Vincristine is combined with Pralatrexate. Pralsetinib The excretion of Vincristine can be decreased when combined with Pralsetinib. Pramocaine The risk or severity of methemoglobinemia can be increased when Vincristine is combined with Pramocaine. Pravastatin Pravastatin may decrease the excretion rate of Vincristine which could result in a higher serum level. Somatostatin The metabolism of Vincristine can be decreased when combined with Somatostatin. Somatotropin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Vincristine. Somatrogon The metabolism of Vincristine can be increased when combined with Somatrogon. Sorafenib The excretion of Vincristine can be decreased when combined with Sorafenib. Sotagliflozin The excretion of Vincristine can be decreased when combined with Sotagliflozin. Sotorasib The serum concentration of Vincristine can be decreased when it is combined with Sotorasib. Spesolimab The risk or severity of adverse effects can be increased when Vincristine is combined with Spesolimab. Spironolactone Spironolactone may decrease the excretion rate of Vincristine which could result in a higher serum level. St. John's Wort The serum concentration of Vincristine can be decreased when it is combined with St. John's Wort. Stavudine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Stavudine. Stiripentol The metabolism of Vincristine can be decreased when combined with Stiripentol. Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Vincristine. Succinylcholine Succinylcholine may increase the neurotoxic activities of Vincristine. Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Vincristine. Sulfasalazine The risk or severity of adverse effects can be increased when Vincristine is combined with Sulfasalazine. Sulfinpyrazone The metabolism of Vincristine can be increased when combined with Sulfinpyrazone. Sulpiride Sulpiride may increase the neurotoxic activities of Vincristine. Sultopride Vincristine may increase the neurotoxic activities of Sultopride. Sumatriptan The excretion of Sumatriptan can be decreased when combined with Vincristine. Sunitinib The metabolism of Sunitinib can be decreased when combined with Vincristine. Suvorexant The excretion of Vincristine can be decreased when combined with Suvorexant. Tacrine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrine is combined with Vincristine. Tacrolimus Tacrolimus may increase the immunosuppressive activities of Vincristine. Tadalafil The metabolism of Vincristine can be decreased when combined with Tadalafil. Tafamidis The serum concentration of Vincristine can be increased when it is combined with Tafamidis. Talazoparib The serum concentration of Talazoparib can be increased when it is combined with Vincristine. Tamoxifen The excretion of Vincristine can be decreased when combined with Tamoxifen. Tasimelteon The metabolism of Vincristine can be decreased when combined with Tasimelteon. Taurocholic acid Taurocholic acid may increase the excretion rate of Vincristine which could result in a lower serum level and potentially a reduction in efficacy. Tazemetostat The metabolism of Vincristine can be decreased when combined with Tazemetostat. Technetium The excretion of Technetium Tc-99m mebrofenin can be decreased when combined with Vincristine. Technetium The serum concentration of Vincristine can be increased when it is combined with Technetium Tc-99m sestamibi. Tecovirimat The metabolism of Vincristine can be increased when combined with Tecovirimat. Tegafur The metabolism of Tegafur can be decreased when combined with Vincristine. Tegaserod The serum concentration of Vincristine can be increased when it is combined with Tegaserod. Telaprevir The excretion of Vincristine can be decreased when combined with Telaprevir. Telithromycin The metabolism of Vincristine can be decreased when combined with Telithromycin. Telmisartan Telmisartan may decrease the excretion rate of Vincristine which could result in a higher serum level. Telotristat ethyl The serum concentration of Vincristine can be decreased when it is combined with Telotristat ethyl. Temozolomide The risk or severity of adverse effects can be increased when Vincristine is combined with Temozolomide. Temsirolimus The excretion of Vincristine can be decreased when combined with Temsirolimus. Teniposide Teniposide may increase the neurotoxic activities of Vincristine. Tenofovir alafenamide The metabolism of Vincristine can be decreased when combined with Tenofovir alafenamide. Tenofovir disoproxil The serum concentration of Vincristine can be increased when it is combined with Tenofovir disoproxil. Tepotinib The serum concentration of Vincristine can be increased when it is combined with Tepotinib. Teprotumumab The risk or severity of adverse effects can be increased when Vincristine is combined with Teprotumumab. Terbinafine The metabolism of Vincristine can be increased when combined with Terbinafine. Terfenadine The metabolism of Vincristine can be decreased when combined with Terfenadine. Teriflunomide The risk or severity of adverse effects can be increased when Vincristine is combined with Teriflunomide. Testosterone The metabolism of Vincristine can be increased when combined with Testosterone. Testosterone cypionate The metabolism of Vincristine can be decreased when combined with Testosterone cypionate. Testosterone enanthate The metabolism of Vincristine can be decreased when combined with Testosterone enanthate. Tetracaine The risk or severity of methemoglobinemia can be increased when Vincristine is combined with Tetracaine. Tetracycline The metabolism of Vincristine can be decreased when combined with Tetracycline. Tezacaftor The metabolism of Vincristine can be decreased when combined with Tezacaftor. Thalidomide The risk or severity of peripheral neuropathy can be increased when Thalidomide is combined with Vincristine. Thiamylal The metabolism of Vincristine can be increased when combined with Thiamylal. Thiethylperazine Thiethylperazine may increase the neurotoxic activities of Vincristine. Thioridazine Vincristine may increase the neurotoxic activities of Thioridazine. Thiotepa The risk or severity of adverse effects can be increased when Vincristine is combined with Thiotepa. Thiothixene Vincristine may increase the neurotoxic activities of Thiothixene. Ticagrelor The excretion of Vincristine can be decreased when combined with Ticagrelor. Tick-borne The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Vincristine. Tinidazole Vincristine may decrease the excretion rate of Tinidazole which could result in a higher serum level. Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Vincristine. Tipranavir The serum concentration of Vincristine can be decreased when it is combined with Tipranavir. Tivozanib Tivozanib may decrease the excretion rate of Vincristine which could result in a higher serum level. Tixocortol The risk or severity of adverse effects can be increased when Vincristine is combined with Tixocortol. Tocilizumab The metabolism of Vincristine can be increased when combined with Tocilizumab. Tofacitinib Vincristine may increase the immunosuppressive activities of Tofacitinib. Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Vincristine. Topiramate The metabolism of Vincristine can be increased when combined with Topiramate. Topotecan The risk or severity of adverse effects can be increased when Vincristine is combined with Topotecan. Torasemide The excretion of Torasemide can be decreased when combined with Vincristine. Toremifene The excretion of Vincristine can be decreased when combined with Toremifene. Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Vincristine. Trabectedin The risk or severity of adverse effects can be increased when Vincristine is combined with Trabectedin. Trastuzumab Trastuzumab may increase the neutropenic activities of Vincristine. Trastuzumab emtansine The metabolism of Trastuzumab emtansine can be decreased when combined with Vincristine. Trazodone The serum concentration of Vincristine can be decreased when it is combined with Trazodone. Tretinoin The metabolism of Vincristine can be decreased when combined with Tretinoin. Triamcinolone The metabolism of Vincristine can be increased when combined with Triamcinolone. Triazolam The metabolism of Vincristine can be decreased when combined with Triazolam. Triclabendazole The metabolism of Vincristine can be decreased when combined with Triclabendazole. Trifluoperazine Vincristine may increase the neurotoxic activities of Trifluoperazine. Triflupromazine Triflupromazine may increase the neurotoxic activities of Vincristine. Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Vincristine. Trilaciclib The serum concentration of Vincristine can be increased when it is combined with Trilaciclib. Trilostane The risk or severity of adverse effects can be increased when Vincristine is combined with Trilostane. Trimethoprim The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Vincristine. Trimipramine The serum concentration of Trimipramine can be increased when it is combined with Vincristine. Troglitazone The metabolism of Vincristine can be increased when combined with Troglitazone. Troleandomycin The metabolism of Vincristine can be decreased when combined with Troleandomycin. Tubocurarine Vincristine may increase the neurotoxic activities of Tubocurarine. Tucatinib Tucatinib may decrease the excretion rate of Vincristine which could result in a higher serum level. Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Vincristine. Typhoid Vaccine Live The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Vincristine. Typhoid The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Vincristine. Ubidecarenone The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Ubidecarenone. Ubrogepant The serum concentration of Vincristine can be increased when it is combined with Ubrogepant. Udenafil The metabolism of Vincristine can be decreased when combined with Udenafil. Umbralisib The excretion of Vincristine can be decreased when combined with Umbralisib. Umeclidinium The serum concentration of Vincristine can be increased when it is combined with Umeclidinium. Upadacitinib The risk or severity of adverse effects can be increased when Vincristine is combined with Upadacitinib. Ursodeoxycholic acid Ursodeoxycholic acid may decrease the excretion rate of Vincristine which could result in a higher serum level. Valbenazine The metabolism of Vincristine can be decreased when combined with Valbenazine. Valproate bismuth Vincristine may increase the neurotoxic activities of Valproate bismuth. Valproic acid The metabolism of Vincristine can be decreased when combined with Valproic acid. Valsartan The excretion of Valsartan can be decreased when combined with Vincristine. Vandetanib The excretion of Vincristine can be decreased when combined with Vandetanib. Vardenafil The excretion of Vincristine can be decreased when combined with Vardenafil. Varicella zoster The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Vincristine. Varicella zoster The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Vincristine. Vasopressin Vincristine may increase the fluid retaining and vasopressor activities of Vasopressin. Vedolizumab The risk or severity of adverse effects can be increased when Vincristine is combined with Vedolizumab. Velpatasvir The excretion of Vincristine can be decreased when combined with Velpatasvir. Vemurafenib The serum concentration of Vincristine can be increased when it is combined with Vemurafenib. Venetoclax The excretion of Vincristine can be decreased when combined with Venetoclax. Venlafaxine Venlafaxine may increase the excretion rate of Vincristine which could result in a lower serum level and potentially a reduction in efficacy. Verapamil The excretion of Vincristine can be decreased when combined with Verapamil. Vibrio cholerae The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Vincristine. Vilanterol The risk or severity of adverse effects can be increased when Vincristine is combined with Vilanterol. Viloxazine The metabolism of Vincristine can be decreased when combined with Viloxazine. Vinblastine The metabolism of Vincristine can be increased when combined with Vinblastine. Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Vincristine. Vinflunine The serum concentration of Vinflunine can be increased when it is combined with Vincristine. Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Vincristine. Viomycin Vincristine may increase the neurotoxic activities of Viomycin. Vismodegib Vismodegib may decrease the excretion rate of Vincristine which could result in a higher serum level. Vitamin E The metabolism of Vincristine can be increased when combined with Vitamin E. Voclosporin The serum concentration of Vincristine can be increased when it is combined with Voclosporin. Vonoprazan The metabolism of Vincristine can be decreased when combined with Vonoprazan. Vorapaxar The excretion of Vincristine can be decreased when combined with Vorapaxar. Voriconazole The metabolism of Vincristine can be decreased when combined with Voriconazole. Vorinostat The risk or severity of adverse effects can be increased when Vincristine is combined with Vorinostat. Vortioxetine The metabolism of Vincristine can be decreased when combined with Vortioxetine. Voxelotor The serum concentration of Vincristine can be increased when it is combined with Voxelotor. Voxilaprevir The excretion of Vincristine can be decreased when combined with Voxilaprevir. Warfarin The metabolism of Vincristine can be increased when combined with Warfarin. Yellow fever vaccine The risk or severity of infection can be increased when the Yellow fever vaccine is combined with Vincristine. Zafirlukast The metabolism of Vincristine can be decreased when combined with Zafirlukast. Pregnancy and Lactation FDA Pregnancy category D Pregnancy There is a possibility of birth defect if either partner is using vincristine at the time of conception, or if it is taken during pregnancy. It may also harm the baby in other ways if used during pregnancy. Use effective birth control while you are taking this medication, and tell the doctor immediately if you become pregnant. Breast-feeding It is not known whether vincristine passes into breast milk. Because of the risk of harm to the infant, women should not breastfeed while receiving vincristine. How should this medicine be used?

Vincristine comes as a solution (liquid) to be injected intravenously (into a vein) by a doctor or nurse in a medical facility. It is usually given once a week. The length of treatment depends on the types of drugs you are taking, how well your body responds to them, and the type of cancer you have. Your doctor may need to delay your treatment or change your dose if you experience certain side effects. It is important for you to…

References

Add references, clinical guidelines, textbooks, journal articles, or trusted medical sources here. You can edit this area from the RX Article Professional Blocks panel.

More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   Vasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    Cholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    Imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    A thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    Propylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    Methimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    Mirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain? Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)